CA-CEQUENCE-SECURITY
15.12.2021 15:02:05 CET | Business Wire | Press release
Cequence Security , the leader in API security, today announced it has closed $60 million in Series C funding led by new investor Menlo Ventures. Additional participation comes from new investors ICON Ventures, Telstra Ventures and HarbourVest Partners. Existing investors Shasta Ventures, Dell Technologies Capital and T-Mobile Ventures also participated in this funding round. The latest round of funding brings total investment in the company to $100 million.
This new financing comes on the heels of record growth for Cequence , driven by advancements in business applications in response to the COVID-19 pandemic. Across multiple industries, companies have accelerated their digital transformation projects and deployed a growing number of new APIs, but in the process, they have overlooked traditional security reviews and governance best practices.
Cequence’s API security solution is the most comprehensive platform on the market and its success in protecting 2 billion API transactions per day is unmatched by competitors. Cequence works tirelessly to help organizations protect their APIs and their businesses with API inventory tracking, risk assessment and threat prevention—all performed natively and at runtime.
This hard work has proven fruitful, as Cequence services over 85 brands worldwide, including several Fortune 500 and 100 companies in markets ranging from banking and beauty, to retail and consumer mobile apps.
VP Analyst at Gartner, Mark O’Neill and Jeremy D'Hoinne, emphasizes in 2021 Gartner® “Hype Cycle™ for Application Security, 2021” report .
“Many organizations lack visibility of their APIs, as many APIs are used as part of web or mobile applications and not published directly. This means that a key requirement of API threat protection is API discovery, since, as every security professional knows, you can’t secure what you don’t know.” 1
“As an active cybersecurity investor, I’ve looked at countless API security vendors, but I’m placing my bets on Cequence—as is the market. Among their impressive roster of customers, you’ll find several household names and Fortune 500 organizations, which speaks to their ability to meet the API protection demands of the largest and most demanding enterprise businesses,” said Venky Ganesan, partner at Menlo Ventures. “Part of the appeal is superior product architecture. Cequence can stand alone: It is the only solution that provides visibility and inline response mitigation to attacks on APIs. It’s the only solution out there that doesn’t need to signal other products for mitigation.”
The funding will support new enhancements to Cequence’s API security solutions and the expansion of its product offerings. It will also help the company break into new regions in the United States and Europe, as well as new markets in Asia and Australia. In turn, Cequence will be looking to aggressively hire and grow its team within these geographies. As part of the transaction, Venky Ganesan of Menlo Ventures will also join the company’s board.
“From social networks to online shopping and financial services, so many aspects of our lives and digital experiences are tied to APIs. That’s why it’s critical to be able to manage your entire API inventory to address security gaps and protect against rising API threats that may lead to fraud and data loss,” said Larry Link, CEO of Cequence Security. “We’re thrilled that our new and existing investors recognize this growing market need and are eager to support our mission to protect organizations—and users—in this digital-first world.”
To learn more about Cequence’s API visibility and protection capabilities or to schedule a demo, visit: https://www.cequence.ai/
1 Gartner, “Hype Cycle™ for Application Security, 2021, Joerg Fritsch, 12 July 2021.
Gartner Disclaimer:
GARTNER and HYPE CYCLE are a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission.
About Cequence Security
Organizations trust Cequence Security to protect their APIs and web applications with the most effective and adaptive defense against online fraud, business logic attacks, exploits and unintended data leakage; which enables them to remain resilient in today’s ever-changing business and threat landscape. Cequence is the only API Security Platform offering that unifies API discovery, inventory tracking, risk analysis and remediation with proven, real-time threat protection against ever evolving online attacks. Learn more at www.cequence.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005012/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
